CVRX (CVRX) Q2 FY26 earnings call

CVRX reported Q2 FY26 revenue growth of 16% and improved gross margin, but lowered its full-year guidance due to significant sales force productivity challenges and ongoing reimbursement hurdles with a major Medicare Advantage payer. Management is implementing measures to address sales execution and continues to make progress on patient access and clinical evidence, maintaining confidence in the long-term market opportunity despite short-term headwinds and a DOJ inquiry.